Viaskin Peanut 250 mcg

BIOLOGICAL3 trials

Sponsors

DBV Technologies

Conditions

Peanut Allergy

Phase 2

Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy

CompletedNCT01675882

DBV TechnologiesPeanut Allergy

Start: 2012-08-31End: 2014-07-31Updated: 2021-10-27

Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children

CompletedNCT01955109

DBV TechnologiesPeanut Allergy

Start: 2013-09-30End: 2016-09-30Updated: 2022-06-30

Phase 3

Safety Study of Viaskin Peanut to Treat Peanut Allergy

CompletedNCT02916446

DBV TechnologiesPeanut Allergy

Start: 2016-10-31End: 2020-10-07Updated: 2021-02-03

Related Papers

Long-Term Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: An Open-Label Active Treatment (REALISE Study).

2025-02-272 citations

Effect of Varying Doses of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Exposure Among Patients With Peanut Sensitivity

JAMA2017-11-14215 citations